4-Methoxybenzyl alcohol
Based on 1 Customer Validation
4-Methoxybenzyl alcohol (P-Methoxy-benzyl alcoho; (4-Methoxyphenyl) methanol) is a naturally derived volatile aromatic compound. 4-Methoxybenzyl alcohol upregulates the phosphorylation level of PI3K/Akt pathway proteins, downregulates the expression of pro-inflammatory factors, increases the content of tight junction proteins occludin and claudin-5, and alleviates structural damage to the blood-brain barrier. 4-Methoxybenzyl alcohol improves the decrease in viability and NO level of cerebral microvascular endothelial cells induced by oxygen-glucose deprivation/reperfusion, and reduces the release of lactate dehydrogenase. 4-Methoxybenzyl alcohol serves as a substrate in the two-phase persulfate-mediated electro-oxidation system, where it is directionally oxidized to p-anisaldehyde. 4-Methoxybenzyl alcohol acts as a substrate for wild-type fungal aryl alcohol oxidase. 4-Methoxybenzyl alcohol can be used in studies related to ischemic stroke, as well as in research across various fields such as chemical synthesis, including the synthesis of fragrances and flavorings.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 105-13-5
- Formula: C8H10O2
- Molecular Weight:138.17
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
IL-6 |
IL-1β |
TNF-α |
Claudin-5 |
eNOS |
Akt |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KB | IC50 |
>20000 ng/mL
Compound: 2
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 8759172] |
4-Methoxybenzyl alcohol (4-MA) (25-800 µM; 36 h) shows no cytotoxicity to bEnd.3 cells at concentrations up to 800 µM, and significantly increases the survival rate of bEnd.3 cells injured by OGD/Rep, with the strongest effect observed at the concentration of 200 µM[1].
4-Methoxybenzyl alcohol (50-200 µM; 36 h post-OGD/Rep) reduces LDH release and increases NO levels in bEnd.3 cells injured by OGD/Rep[1].
4-Methoxybenzyl alcohol (200 µM; 36 h post-OGD/Rep) upregulates the expression of tight junction proteins occludin and claudin-5 in OGD/Rep-injured bEnd.3 cells, and activates the PI3K/AKT signaling pathway, as evidenced by increased phosphorylation levels of AKT and eNOS[1].
4-Methoxybenzyl alcohol (200 µM; 36 h post-OGD/Rep) reduces the levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in OGD/Rep-injured bEnd.3 cells[1].
4-Methoxybenzyl alcohol can be oxidized by wild-type and mutant AAO from Pleurotus eryngii, among which the I500M mutant exhibits the highest catalytic efficiency[2].
4-Methoxybenzyl alcohol serves as a substrate in the two-phase persulfate-mediated electro-oxidation system, and undergoes directional oxidation to p-anisaldehyde[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mouse brain microvascular endothelial cells (bEnd.3)
-
Concentration:25, 5, 100, 200, 400, 800 µM
-
Incubation Time:36 h; 36 h (prior to OGD/Rep)
-
Result:Had no significant effect on the viability of untreated bEnd.3 cells.
Increased viability of OGD/Rep-injured bEnd.3 cells from 57.97% to 87.77% at 200 µM, to 83.90% at 100 µM, and to 79.74% at 50 µM.
-
Cell Line:OGD/Rep-injured mouse brain microvascular endothelial cells (bEnd.3)
-
Concentration:50, 100, 200 µM
-
Incubation Time:36 h (post-OGD/Rep)
-
Result:Reduced TNF-α from 45.09 ng/l to 37.89 ng/l, IL-1β from 7.37 ng/l to 3.57 ng/l, and IL-6 from 23.44 ng/l to 18.20 ng/l at 200 µM.
-
Cell Line:OGD/Rep-injured mouse brain microvascular endothelial cells (bEnd.3)
-
Concentration:200 µM
-
Incubation Time:36 h (post-OGD/Rep)
-
Result:Significantly increased the mean optical density (MOD) of occludin and claudin-5 compared to the OGD/Rep group.
-
Cell Line:OGD/Rep-injured mouse brain microvascular endothelial cells (bEnd.3)
-
Concentration:200 µM
200 µM + 50 µM LY294002 (HY-10108) -
Incubation Time:36 h (post-OGD/Rep)
-
Result:Significantly upregulated the p-AKT/AKT and p-eNOS/eNOS ratios compared to the OGD/Rep group.
Abolished the upregulation effect on p-AKT/AKT and p-eNOS/eNOS ratios when co-treated with 50 µM LY294002.
Chemical Information
-
CAS No. 105-13-5
-
Appearance <22°C Solid,>25°C Liquid
-
Molecular Weight 138.17
-
Formula C8H10O2
-
Color Colorless to off-white
-
SMILES
COC1=CC=C(CO)C=C1
-
Synonyms
P-Methoxy-benzyl alcoho; (4-Methoxyphenyl)methanol
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 200 mg/mL (1447.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (36.19 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (36.19 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.2375 mL | 36.1873 mL | 72.3746 mL | 180.9365 mL |
| 5 mM | 1.4475 mL | 7.2375 mL | 14.4749 mL | 36.1873 mL | |
| 10 mM | 0.7237 mL | 3.6187 mL | 7.2375 mL | 18.0937 mL | |
| 15 mM | 0.4825 mL | 2.4125 mL | 4.8250 mL | 12.0624 mL | |
| 20 mM | 0.3619 mL | 1.8094 mL | 3.6187 mL | 9.0468 mL | |
| 25 mM | 0.2895 mL | 1.4475 mL | 2.8950 mL | 7.2375 mL | |
| 30 mM | 0.2412 mL | 1.2062 mL | 2.4125 mL | 6.0312 mL | |
| 40 mM | 0.1809 mL | 0.9047 mL | 1.8094 mL | 4.5234 mL | |
| 50 mM | 0.1447 mL | 0.7237 mL | 1.4475 mL | 3.6187 mL | |
| 60 mM | 0.1206 mL | 0.6031 mL | 1.2062 mL | 3.0156 mL | |
| 80 mM | 0.0905 mL | 0.4523 mL | 0.9047 mL | 2.2617 mL | |
| 100 mM | 0.0724 mL | 0.3619 mL | 0.7237 mL | 1.8094 mL |